Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ENDRA Life SciencesNDRA -0.90%25 Receivables Turnover is 0.00 as of Mar. 2026. GuruFocus rates NDRA with a GF Score™ of 25/100. The stock has 2 warning signs investors should review. Among 202 Medical Diagnostics & Research companies, ENDRA Life Sciences ranks worse than 495049.01% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. ENDRA Life Sciences's Revenue for the
three
months ended in Mar. 2026 was $0.00 Mil. ENDRA Life Sciences's average Accounts Receivable for the
three
months ended in Mar. 2026 was $0.00 Mil.
ENDRA Life Sciences (NAS:NDRA) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
ENDRA Life Sciences Receivables Turnover Related Terms
ENDRA Life Sciences Receivables Turnover Historical Data
* Premium members only.
The historical data trend for ENDRA Life Sciences's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NDRA vs BIAF, ADVB, MBAI: Receivables Turnover Comparison
For the Diagnostics & Research subindustry, ENDRA Life Sciences's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ENDRA Life Sciences Receivables Turnover vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, ENDRA Life Sciences's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where ENDRA Life Sciences's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ENDRA Life Sciences (NDRA) has a Receivables Turnover of 0.00 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on ENDRA Life Sciences and its competitors. According to the industry distribution chart, ENDRA Life Sciences ranks #999999 out of 202 companies in the Medical Diagnostics & Research industry.
Is ENDRA Life Sciences' Receivables Turnover too high?
ENDRA Life Sciences' current Receivables Turnover is 0.00. Based on the distribution chart, ENDRA Life Sciences ranks #999999 out of 202 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, ENDRA Life Sciences has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does ENDRA Life Sciences' Receivables Turnover compare to BIAF and ADVB?
According to the Medical Diagnostics & Research industry distribution chart, ENDRA Life Sciences ranks #999999 out of 202 companies for Receivables Turnover. This places ENDRA Life Sciences in the lower half of its industry. The industry median Receivables Turnover is 5.38. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Diagnostics & Research company?
The median Receivables Turnover among Medical Diagnostics & Research companies is 5.38, based on 202 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on ENDRA Life Sciences and its competitors. For the Medical Diagnostics & Research industry, the median Receivables Turnover is 5.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ENDRA Life Sciences's current Receivables Turnover is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ENDRA Life Sciences stock overvalued right now?
ENDRA Life Sciences (NDRA) has a current Receivables Turnover of 0.00. The current Receivables Turnover is 0.00. ENDRA Life Sciences' overall GF Score™ is 25/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For ENDRA Life Sciences (NDRA), the current Receivables Turnover is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
ENDRA Life Sciences Inc is engaged in the development of thermo-acoustic enhanced ultrasound (TAEUS) technology to improve the capabilities of clinical diagnostic ultrasound. The company's technology is used to measure tissue composition, including the assessment of fat in the liver, and is being developed for additional clinical applications such as tissue temperature monitoring.
25GF Score
Get the complete analysis for NDRA
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NDRA has been successfully added to your 
